BR112023017624A2 - Derivados de alfa-d-galactopiranosídeo substituídos com triazolil-metila - Google Patents
Derivados de alfa-d-galactopiranosídeo substituídos com triazolil-metilaInfo
- Publication number
- BR112023017624A2 BR112023017624A2 BR112023017624A BR112023017624A BR112023017624A2 BR 112023017624 A2 BR112023017624 A2 BR 112023017624A2 BR 112023017624 A BR112023017624 A BR 112023017624A BR 112023017624 A BR112023017624 A BR 112023017624A BR 112023017624 A2 BR112023017624 A2 BR 112023017624A2
- Authority
- BR
- Brazil
- Prior art keywords
- triazolyl
- alpha
- methyl
- derivatives substituted
- galactopyranoside
- Prior art date
Links
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
derivados de alfa-d-galactopiranosídeo substituídos com triazolil-metila. a presente invenção se refere aos inibidores de galectina-3 de fórmula (i) e sais farmaceuticamente aceitáveis dos mesmos, às composições farmacêuticas compreendendo tais compostos e seus usos médicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021055348 | 2021-03-03 | ||
| PCT/EP2022/055224 WO2022184755A1 (en) | 2021-03-03 | 2022-03-02 | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017624A2 true BR112023017624A2 (pt) | 2023-10-10 |
Family
ID=80682779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017624A BR112023017624A2 (pt) | 2021-03-03 | 2022-03-02 | Derivados de alfa-d-galactopiranosídeo substituídos com triazolil-metila |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240109930A1 (pt) |
| EP (1) | EP4301748A1 (pt) |
| JP (1) | JP2024509421A (pt) |
| KR (1) | KR20230154221A (pt) |
| CN (1) | CN116888113A (pt) |
| AU (1) | AU2022228660A1 (pt) |
| BR (1) | BR112023017624A2 (pt) |
| CA (1) | CA3209917A1 (pt) |
| CL (1) | CL2023002578A1 (pt) |
| IL (1) | IL305581A (pt) |
| MX (1) | MX2023010241A (pt) |
| TW (1) | TW202300146A (pt) |
| WO (1) | WO2022184755A1 (pt) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| CA2926917C (en) | 2012-10-10 | 2021-01-05 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| IN2015DN02573A (pt) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| JP6366598B2 (ja) | 2012-11-15 | 2018-08-01 | タフツ ユニバーシティー | ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット |
| EP3250581B1 (en) | 2015-01-30 | 2021-01-20 | Galecto Biotech AB | Alpha-d-galactoside inhibitors of galectins |
| IL293770B2 (en) | 2015-07-06 | 2023-07-01 | Gilead Sciences Inc | Modulators of cot and methods of using them |
| JP2020519597A (ja) | 2017-05-12 | 2020-07-02 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身性インスリン抵抗性障害の治療用化合物およびその使用 |
| AU2018265571B2 (en) | 2017-05-12 | 2022-09-29 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| US20220144818A1 (en) * | 2019-04-10 | 2022-05-12 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US20230014870A1 (en) | 2019-07-03 | 2023-01-19 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2021004940A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| KR20220044785A (ko) | 2019-08-09 | 2022-04-11 | 이도르시아 파마슈티컬스 리미티드 | (헤테로)아릴-메틸-티오-베타-d-갈락토피라노시드 유도체 |
| ES2974680T3 (es) | 2019-08-09 | 2024-07-01 | Idorsia Pharmaceuticals Ltd | Derivados de (2-acetamidil)tio-beta-D-galactopiranósidos |
| KR20220047585A (ko) | 2019-08-15 | 2022-04-18 | 이도르시아 파마슈티컬스 리미티드 | 2-히드록시시클로알칸-1-카르바모일 유도체 |
| PL4021904T3 (pl) | 2019-08-29 | 2024-05-13 | Idorsia Pharmaceuticals Ltd | Pochodne alfa-d-galaktopiranozydu |
-
2022
- 2022-03-02 AU AU2022228660A patent/AU2022228660A1/en active Pending
- 2022-03-02 IL IL305581A patent/IL305581A/en unknown
- 2022-03-02 WO PCT/EP2022/055224 patent/WO2022184755A1/en active Application Filing
- 2022-03-02 KR KR1020237033375A patent/KR20230154221A/ko unknown
- 2022-03-02 MX MX2023010241A patent/MX2023010241A/es unknown
- 2022-03-02 EP EP22708569.3A patent/EP4301748A1/en active Pending
- 2022-03-02 TW TW111107565A patent/TW202300146A/zh unknown
- 2022-03-02 JP JP2023552539A patent/JP2024509421A/ja active Pending
- 2022-03-02 CA CA3209917A patent/CA3209917A1/en active Pending
- 2022-03-02 CN CN202280017484.3A patent/CN116888113A/zh active Pending
- 2022-03-02 US US18/548,833 patent/US20240109930A1/en active Pending
- 2022-03-02 BR BR112023017624A patent/BR112023017624A2/pt unknown
-
2023
- 2023-08-31 CL CL2023002578A patent/CL2023002578A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240109930A1 (en) | 2024-04-04 |
| WO2022184755A1 (en) | 2022-09-09 |
| IL305581A (en) | 2023-10-01 |
| EP4301748A1 (en) | 2024-01-10 |
| AU2022228660A1 (en) | 2023-10-19 |
| TW202300146A (zh) | 2023-01-01 |
| CL2023002578A1 (es) | 2024-03-22 |
| JP2024509421A (ja) | 2024-03-01 |
| KR20230154221A (ko) | 2023-11-07 |
| CN116888113A (zh) | 2023-10-13 |
| MX2023010241A (es) | 2023-09-12 |
| CA3209917A1 (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
| BRPI1011657A2 (pt) | derivados aminopropiônicos substituídos como inibidores de neprilisina | |
| BR112015022758A2 (pt) | derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia | |
| BR112018073524A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição. | |
| CL2022003646A1 (es) | Derivados de amidopirimidona | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| BR112021023770A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112023003832A2 (pt) | Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos | |
| UY39171A (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| BR112022006608A2 (pt) | Inibidores orais do fator d do complemento | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| BR112023017624A2 (pt) | Derivados de alfa-d-galactopiranosídeo substituídos com triazolil-metila | |
| BR112022021712A2 (pt) | Processos para a preparação de um inibidor de quinase | |
| BR112021023765A2 (pt) | Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto | |
| BR112022010943A2 (pt) | Análogos de nucleosídeos substituídos como inibidores de prmt5 | |
| CO2023010155A2 (es) | Derivados de pirazolamida | |
| BR112021024999A2 (pt) | Inibidores de prmt5 | |
| BRPI0720251B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo | |
| BR112023025850A2 (pt) | Inibidores da nicotinamida ripk1 | |
| BR112023016986A2 (pt) | Compostos de aminopirimidina e métodos de seu uso | |
| BR112023016970A2 (pt) | Compostos heterocíclicos antivirais | |
| BR112021025877A2 (pt) | Derivados de amina terciária e seus usos para tratar uma infecção viral | |
| BR112022008717A2 (pt) | Composto de fórmula, um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável ou éster deste, inibidor de aurora quinase, composição farmacêutica, e uso do composto |